There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Antares Pharma (ATRS) and Durect (DRRX) with bullish sentiments.
Antares Pharma (ATRS)
In a report released today, Oren Livnat from H.C. Wainwright reiterated a Buy rating on Antares Pharma, with a price target of $5.00. The company’s shares closed last Monday at $3.11.
According to TipRanks.com, Livnat is a 3-star analyst with an average return of 1.6% and a 43.1% success rate. Livnat covers the Healthcare sector, focusing on stocks such as Collegium Pharmaceutical, Zynerba Pharmaceuticals, and Taiwan Liposome Company.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Antares Pharma with a $5.00 average price target.
See today’s analyst top recommended stocks >>
Durect (DRRX)
In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Durect, with a price target of $5.50. The company’s shares closed last Monday at $1.72.
According to TipRanks.com, Arce is a 5-star analyst with an average return of 11.1% and a 39.3% success rate. Arce covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Collegium Pharmaceutical, and Aurinia Pharmaceuticals.
Currently, the analyst consensus on Durect is a Strong Buy with an average price target of $4.72.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on DRRX:
